Diabetic Macular Edema

Focused updates on the management of diabetic macular edema, including treatment advances, clinical trial results, and real-world data. Explores evolving standards of care and patient outcomes.

Diabetic Macular Edema

AI-OCT reduces false-positive referrals for diabetic macular edema

Adding an artificial intelligence (AI)–based optical coherence tomography (AI-OCT) system to diabetic retinopathy screening substantially reduced false-positive referrals for diabetic macular edema (DME) while maintaining referral sensitivity, according to a study. The study included a prospective validation phase and a multicenter randomized clinical trial involving patients referred from a territory-wide diabetic retinopathy screening program. In... ...

Retina

Real-world study finds similar efficacy between faricimab and aflibercept in DMO

Faricimab and aflibercept 2 mg produced comparable short-term visual and anatomical outcomes in patients with diabetic macular oedema (DMO), according to a...

$FDA approves fully preloaded non-diffractive IOL$

Retina

FDA approves extended dosing intervals for aflibercept HD in wAMD and DME

The U.S. Food and Drug Administration has approved extended dosing intervals for EYLEA HD (aflibercept), allowing treatment up to every 20 weeks...

Retina

Worldwide diabetes “epidemic” is increasing the risk of irreversible vision loss

In another live recording of The Spotlight Series Podcast from the Hawaiian Eye Meeting, host Mario Nacinovich and Judy Kim, MD, of...

Latest Diabetic Macular Edema Videos

Diabetic Macular Edema

Hawaiian Eye Meeting update: TKI therapy may reduce treatment burden in DME and wet AMD

Diabetic Macular Edema

Vorolanib offers a different mechanism of action for AMD, DME

Diabetic Macular Edema

IRIS Registry data shows early aflibercept 8 mg use allows for 12-week injection intervals in AMD and DME cohorts

Retina Care 360

ASRS 2025: Phase 2 VERONA study shows durable treatment outcomes with EYP-1901 for DME

Retina Care 360

ASRS 2025: Imaging study shows decreased leakage after treatment with axitinib hydrogel for diabetic retinopathy

Conference Roundup

VERONA 24-week results: efficacy of vorolanib intravitreal insert in DME

Retina

Updates from Angiogenesis 2025 meeting detail recent outcomes for EYP-1901 in AMD and DME

Retina

PHOTON trial assesses aflibercept 8 mg for diabetic macular edema

Diabetic Macular Edema

Real-world study offers early insights into aflibercept 8 mg for DME

Early real-world data from the global SPECTRUM study presented at AAO 2025 show that aflibercept 8 mg is being successfully administered to both treatment-naïve (TN) and previously treated (PT) patients...

Diabetic Macular Edema

High-dose aflibercept stabilizes vision and reduces retinal thickness in diabetic macular edema

High-dose aflibercept can stabilize vision and reduce retinal swelling in patients with diabetic macular edema (DME), but many patients still require frequent injections and have persistent macular fluid, according to...

Diabetic Macular Edema

Study finds high treatment satisfaction but moderate quality of life in patients receiving intravitreal injections

Patients with neovascular age-related macular degeneration, diabetic macular edema, and retinal vein occlusion receiving intravitreal injections generally report high treatment satisfaction but only moderate vision-related quality of life, and that...

Diabetic Macular Edema

Prevalence of diabetic macular edema in type 1 diabetes highlighted in new meta-analysis

Diabetic macular edema (DME) affects a substantial proportion of people with type 1 diabetes, with risk strongly linked to disease duration and poor glycemic control, as well as other comorbidities...

Diabetic Macular Edema

Combination therapy improves outcomes in treatment-resistant diabetic macular edema

Combining intravitreal corticosteroids with anti-VEGF therapy resulted in significant short-term improvements in retinal thickness and visual acuity in patients with diabetic macular edema (DME) resistant to monotherapy, without any safety...

Diabetic Macular Edema

Aflibercept 8 mg may lower treatment costs in nAMD and DME compared with faricimab

A new cost analysis suggests that aflibercept 8 mg could provide economic advantages over faricimab in the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Using...

Retina Care 360

ASRS 2025: Phase 2 VERONA study shows durable treatment outcomes with EYP-1901 for DME

Yasha Modi, MD, of NYU Langone Health, gave a presentation at the American Society of Retina Specialists (ASRS) Annual Meeting about the potential to reduce treatment burden with a combination...

4 Mins Watch

Retina

Switching anti-VEGF therapy benefits bevacizumab non-responders in DME

A real-world study has found that patients with diabetic macular oedema (DME) unresponsive to bevacizumab can still achieve visual improvements after switching to ranibizumab or aflibercept. Researchers reviewed 76 patients...